Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

430 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, van der Heijde D, McInnes IB; DISCOVER-2 Study Group. Mease PJ, et al. Among authors: gottlieb ab. Lancet. 2020 Apr 4;395(10230):1126-1136. doi: 10.1016/S0140-6736(20)30263-4. Epub 2020 Mar 13. Lancet. 2020. PMID: 32178766 Clinical Trial.
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A. Elmets CA, et al. Among authors: gottlieb ab. J Am Acad Dermatol. 2021 Feb;84(2):432-470. doi: 10.1016/j.jaad.2020.07.087. Epub 2020 Jul 30. J Am Acad Dermatol. 2021. PMID: 32738429
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
Lebwohl MG, Leonardi CL, Mehta NN, Gottlieb AB, Mendelsohn AM, Parno J, Rozzo SJ, Menter MA. Lebwohl MG, et al. Among authors: gottlieb ab. J Am Acad Dermatol. 2021 Feb;84(2):398-407. doi: 10.1016/j.jaad.2020.09.047. Epub 2020 Sep 19. J Am Acad Dermatol. 2021. PMID: 32961255 Free article. Clinical Trial.
Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial.
Casseres RG, Prussick L, Zancanaro P, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Au SC, Alomran A, Abdat R, Abudu M, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D. Casseres RG, et al. Among authors: gottlieb ab. J Am Acad Dermatol. 2020 Jun;82(6):1524-1526. doi: 10.1016/j.jaad.2020.02.005. Epub 2020 Feb 7. J Am Acad Dermatol. 2020. PMID: 32044410 Clinical Trial. No abstract available.
Axial psoriatic arthritis: An update for dermatologists.
Gottlieb AB, Merola JF. Gottlieb AB, et al. J Am Acad Dermatol. 2021 Jan;84(1):92-101. doi: 10.1016/j.jaad.2020.05.089. Epub 2020 Jul 31. J Am Acad Dermatol. 2021. PMID: 32747079 Free article. Review.
Safety of guselkumab with and without prior TNF-α inhibitor treatment: Pooled results across four studies in patients with psoriatic arthritis.
Rahman P, Boehncke WH, Mease PJ, Gottlieb AB, McInnes IB, Shawi M, Wang Y, Sheng S, Kollmeier AP, Theander E, Yu J, Leibowitz E, Marrache AM, Coates LC. Rahman P, et al. Among authors: gottlieb ab. J Rheumatol. 2023 Jan 15:jrheum.220928. doi: 10.3899/jrheum.220928. Online ahead of print. J Rheumatol. 2023. PMID: 36642439 Free article.
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).
Gisondi P, Gottlieb AB, Elewski B, Augustin M, McBride S, Tsai TF, de la Loge C, Fierens F, López Pinto JM, Tilt N, Lebwohl M. Gisondi P, et al. Among authors: gottlieb ab. Dermatol Ther (Heidelb). 2023 Jan;13(1):315-328. doi: 10.1007/s13555-022-00861-4. Epub 2022 Dec 13. Dermatol Ther (Heidelb). 2023. PMID: 36509889 Free PMC article.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola JF, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Gottlieb AB, Thaçi D, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Coates LC. Merola JF, et al. Among authors: gottlieb ab. Lancet. 2023 Jan 7;401(10370):38-48. doi: 10.1016/S0140-6736(22)02303-0. Epub 2022 Dec 6. Lancet. 2023. PMID: 36495881 Free article. Clinical Trial.
430 results